DOCSLIB.ORG

AT the HEART of DISCOVERY 2019 Heart Research Institute Annual Review Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AT the HEART of DISCOVERY 2019 Heart Research Institute Annual Review Contents HEART RESEARCH INSTITUTE Annual Report 2019 30 YEARS AT THE HEART OF DISCOVERY 2019 Heart Research Institute Annual Review Contents Dr Sabine Kossman 2 2019 Heart Research Institute Annual Review Contents CONTENTS Our Mission 4 HRI in 2019 5 Chairman’s Report 6 Director of Cardiovascular Research Report 7 2019 Research and Media Highlights 8 Atherosclerosis and Vascular Remodelling Group 12 Cardiometabolic Disease Group 13 Cardiovascular Medical Devices Group 14 Cardiovascular Neuroscience Group 15 Cardiovascular-protective Signalling and Drug Discovery Group 16 Clinical Research Group 17 Coronary Diseases Group 18 Haematology Research Group 19 Heart Rhythm and Stroke Prevention Group 20 Thrombosis Group 21 Vascular Complications Group 22 Vascular Immunology Group 23 Fundraising Report 24 Notable Awards 25 Board of Governors 27 3 2019 Heart Research Institute Annual Review Our Mission Our short and OUR MISSION long-term objectives The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives for is to understand the development and our research: progression of atherothrombotic conditions in 1. To investigate mechanisms contributing to which the arteries are narrowed and restricted the pathogenesis of cardiovascular disease. due to a build-up of fatty deposits. 2. To develop new ways to detect symptoms This is being achieved via scientific and clinical of cardiovascular disease before it leads to research work conducted by the scientific clinical problems. groups that make up the HRI, from basic 3. To develop new treatments that can reverse biomedical discovery work, drug discovery the development of heart disease. and development, and devices and device improvement, to clinical trials and clinical 4. To prevent individuals developing initiatives. cardiovascular disease in the future. LOCATIONS 12 SCIENTIFIC GROUPS • 7 Eliza Street, Newtown • Applied Materials (departed July 2019) • Charles Perkins Centre, The University • Atherosclerosis and Vascular Remodelling of Sydney • Cardiac Imaging (departed December 2019) • Cardiometabolic Disease Chairman • Cardiovascular Medical Devices Professor Len Kritharides • Cardiovascular Neuroscience (established Director of Cardiovascular Research January 2019) Professor Shaun Jackson • Cardiovascular-protective Signalling and Drug Chief Executive Officer Discovery (joined July 2019) Dr Stephen Hollings • Clinical Research Deputy Director Research Strategy • Coronary Diseases Professor Ben Freedman OAM • Haematology Research Acting Scientific Director Emeritus Professor Carolyn Geczy • Heart Rhythm and Stroke Prevention • Thrombosis Clinical Director Professor David Celermajer AO • Vascular Complications Associate Directors of Research • Vascular Immunology Management and Education Dr Mary Kavurma (Eliza St) Assoc Professor Simone Schoenwaelder (Charles Perkins Centre) OUR PARTNERSHIPS • Sydney Local Health District and • Charles Perkins Centre, The University Sydney Health Partners of Sydney - Royal Prince Alfred Hospital Australian Business Number - Sydney Research 41 003 209 952 4 2019 Heart Research Institute Annual Review HRI in 2019 HRI IN 2019 PRESENTATIONS Domestic | 71 International | 101 INTERNATIONAL COLLABORATIONS 110+ collaborations across 44 countries STUDENTS TRAINED OR MENTORED Honours students | 18 PhD students | 20 Visiting students | 6 106 190 52 Discoveries published in Citations by external world-wide Scientific projects currently peer-reviewed journals researchers to work published being undertaken by HRI researchers TOTAL INCOME $24,614,272 2019 HRI INCOME Grants $5,910,281 (24.00%) 2019 grant income by funding body Universities Research Block NSW Department National Health $575,158 Grants of Health and Medical (2.30%) $824,199 $1,339,302 Research Council (3.30%) (5.40%) $1,839,666 (7.50%) Fundraising (incl Bequests) $18,703,991 (76.00%) National Heart Australian Other Foundation Research Council $935,077 Download a full list of HRI publications and $32,864 $364,016 (3.80%) presentations: www.hri.org.au/about/reports (0.10%) (1.50%) 5 2019 Heart Research Institute Annual Review Chairman’s Report 2019 CHAIRMAN’S Professor REPORT 2019 Len Kritharides As I write this report we are in the midst of the There has been significant expansion of HRI We were very pleased to have former Minister COVID-19 pandemic. Hundreds of thousands scientific agenda in 2019. There were two Bruce Baird AM join our Board in 2019, and of people have been infected around the world new units: Dr Melissa Farnham established have benefited greatly from his insight and by a previously unheard-of virus, and thousands the Cardiovascular Neuroscience Unit and engagement. Our management team led by have died. After an Australian summer Dr Xuyu Liu established the Cardiovascular- CEO Dr Stephen Hollings has worked very characterised by drought, bushfires and floods, protective Signalling and Drug Discovery Unit hard to continuously improve every aspect of many of our comforting routines have been at HRI. Clinical trials are emerging as major HRI’s processes, including financial reporting, discarded as we face a world full of uncertainty. opportunities for HRI with National Health and information systems, human resources and scientific reporting. Photos from 1918–1919 showing young men Medical Research Council (NHMRC) funding of Associate Professor Sanjay Patel’s clinical trial and women dressed in their finery for a night Proximity to the Royal Prince Alfred Hospital of colchicine in collaboration with Professor on the town while wearing facial masks to (RPAH) and the world-class clinical care it Tony Keech of the NHMRC Clinical Trials Unit, ward off influenza, seemingly implausible just provides has always been a priority for HRI. and a major international initiative into Phase months ago, resonate with all of us today. We were therefore pleased to be able to 2 trials for stroke treatment using a novel Despite the enormous progress we have made recommit to a further five years of occupation blood thinner developed by Professor Shaun in all aspects of medicine in the last 100 years, of the Charles Perkins Centre on The Jackson’s lab. The commercialisation pipeline University of Sydney Camperdown campus. our continuing vulnerability to disease is a at HRI has been strengthened significantly by The opportunities to further expand the constant. It is only rigorous scientific insight a dedicated Board subcommittee led by Mrs footprint of HRI on site with RPAH are being that provides us with the light at the end of the Sandra Boswell, and we have seen a rapidly actively pursued through our partnership tunnel during such bleak times. We fall back on expanding portfolio of commercially exciting with the SLHD, the Centenary Institute, the medical science, its judicious application by our therapeutic and diagnostic agents emerge. Woolcock Institute and The University of political leaders, and community resilience at Our core business of producing leading Sydney to fund a state-of-the art research times of health crisis. biomedical research has been flourishing. facility linked to the planned redevelopment So, what does COVID-19 have to do with the Numerous groups received Category 1 funding of RPAH. work of the Heart Research Institute (HRI)? from the NHMRC, Australian Research There is much to be proud of, and much more Cardiovascular disease is a world-wide scourge Council (ARC) and Heart Foundation this year, to do if we are to provide the clarity of vision that kills far more people annually than we including personal NHMRC Investigator Grant needed to combat cardiovascular disease. have tallied thus far with COVID-19, has done funding for Professor Jackson and a University We are indebted to our resolute supporters so in the Western world for more than 50 years, of Sydney Robinson Fellowship for Dr Anna and donors who have entrusted us to take and in the developing world has outstripped Waterhouse. Our researchers also received this journey. infectious disease as a cause of death. some noteworthy awards (see page 25). Cardiovascular disease is common, deadly and Our Board members have contributed disabling, yet heart disease and its antecedents generously of their time and expertise, keeping Professor Len Kritharides are strangely unrecognised by our community. the organisation’s governance strong, ensuring MBBS, PhD, FRACP, FCSANZ, FAHA, FESC, FACC The research scientists of the HRI generate we are accountable to our donors and Chairman medical science that challenges nihilism and funding body partners, and facilitating strong complacency in heart disease and stroke. partnerships with the Sydney Local Health This is why the work of HRI is so important. District (SLHD) and The University of Sydney. 6 2019 Heart Research Institute Annual Review Director of Cardiovascular Research Report DIRECTOR OF Professor CARDIOVASCULAR Shaun Jackson RESEARCH REPORT It is my pleasure to provide you with an update on the scientific activities at HRI and to share with you the new opportunities and challenges we face in the coming years. As highlighted by our Chairman, Professor Len Kritharides, recent events with the coronavirus pandemic (COVID-19) have profoundly affected us all. We are living in this most challenging
Load more

Recommended publications
  • 150171-AILS 2015 Flyer V3
    1st Australian Innate Lymphocyte Symposium #AILS2015 12 June 2015 Walter and Eliza Hall Institute, Melbourne Gabrielle Belz Andrew Brooks Mariapia Degli-Esposti Dale Godfrey Phil Hansbro Nick Huntington Shaun McColl Stephen Nutt Mark Smyth Sophie Ugolini Eric Vivier Wolfgang Weninger Registration via http://www.trybooking.com (Search AILS2015) Could you be the next Australian leader in medical research? Menzies scholarships open doors Every year the Menzies Foundation inspires and nurtures Australia’s future leaders to take the next step in their careers, by providing access to Australia’s leading postgraduate scholarships. The Foundation supports prestigious postgraduate scholarships and fellowships in medical and allied health research, engineering and law as well as Menzies Scholarships to Harvard in wide range of disciplines. Why does the Menzies Foundation support scholarships? Before he became Australia’s longest-serving prime minister, Robert Gordon Menzies spent his childhood in the small town of Jeparit in rural Victoria. From the age of 13 he secured scholarships to complete his secondary and tertiary education in Melbourne. He went on to an outstanding life of public service in law, politics and national leadership. His extraordinary story exemplifies the transformative power of education. It has been the inspiration for the Menzies Foundation in supporting more than 200 talented young Australians with Menzies scholarships and fellowships. Many Menzies scholars are now leaders in their fields, just like the 2006 NHMRC/RG Menzies Fellow, Dr Nick Huntington. The NHMRC/RG Menzies Fellowship The NHMRC/RG Menzies Fellowship provides for advanced training in health and medical research for two years overseas and a further two years in Australia.
    [Show full text]
  • Anthony Weiss.Pdf
    Anthony S. Weiss Professor Anthony (Tony) Weiss McCaughey Chair in Biochemistry Leader of the Charles Perkins Centre Node in Tissue Engineering and Regenerative Medicine Professor of Biochemistry and Molecular Biotechnology Order of Australia Fellow of the Royal Society of Chemistry Fellow of the Australian Academy of Technology and Engineering Fellow of the Royal Australian Chemical Institute and Chartered Chemist Fellow of the Royal Society of NSW Fellow of the American Institute for Medical and Biological Engineering Fellow of the Australian Institute of Company Directors Fellow of Biomaterials Science and Engineering Fellow of Tissue Engineering and Regenerative Medicine Charles Perkins Centre D17, The University of Sydney, NSW 2006, Australia W: weisslab.info E: [email protected] T: +61 2 9351 3464 Professor Weiss is the McCaughey Chair in Biochemistry, Professor of Biochemistry & Molecular Biotechnology, Leader of the Tissue Engineering & Regenerative Medicine Node at the Charles Perkins Centre, and Professor in the School of Life & Environmental Sciences, and in the Bosch Institute and the Sydney Nano Institute at the University of Sydney. He is a popular conference speaker and regularly contributes to the TERMIS regional chapter meetings and TERMIS world congresses. In addition to 19 grants in the last five years, he is on the Editorial Boards of ACS Biomaterials Science and Engineering (American Chemical Society), APL Bioengineering (American Institute of Physics), Applied Materials Today (Elsevier), Biomaterials (Elsevier), Biomedical Materials (Institute of Physics), BioNanoScience (Springer), Journal of Tissue Engineering (Sage), Journal of Tissue Engineering and Regenerative Medicine (Wiley), Materials Today Bio (Elsevier) and Tissue Engineering (Liebert). He is an inventor on 43 awarded patents in 18 patent families.
    [Show full text]
  • 2007 Annual Report Annual Institute Eye Lions Review Molecular
    Lions Eye Institute ABN 48 106 521 439 2 Verdun Street, Nedlands WA 6009 General Administration & Research Enquiries 9381 0777 Administration & Research Facsimile 9381 0700 07 International +61 8 9381 0777 Clinical Facilities Elsie Gadd Eye Clinic Appointments 9381 0888 Day Surgery Facility 9381 0880 Laser Vision Centre 9381 0758 Clinical Facilities Facsimile 9382 1171 Annual REPORT 20 WWW.LEI.ORG.AU RAZOREYE LEI5693 02/08 Lions Eye Institute 2007 Annual Report Annual Report 2007 Corporate Directory Mission Lions Eye Institute Prof. Ian Constable AO Assoc. Prof. Geoffrey Crawford Administration & Finance Our mission is to achieve excellence Managing Director Director of Surgical Services [email protected] [email protected] Chee-Peng Yao in scientific research and clinical practice 9381 0871 Chief Financial Officer Esther McCloskey [email protected] to prevent blindness. Executive Assistant to Prof. Constable Assoc. Prof. Graham Barrett 9381 0703 [email protected] [email protected] 9381 0882 9381 0872 David Eiszele Dr Jean-Louis deSousa Information Technology Chairman [email protected] & Communications 9381 0777 9381 0747 Yaasin Lutta Dr Adam Gajdatsy Head of Information Technology [email protected] & Communications Research 9381 0763 [email protected] 9381 0786 Prof. P. Elizabeth Rakoczy Dr Antonio Giubilato Director of Research; [email protected] Director, Molecular Ophthalmology 9381 0819 [email protected] Lions Eye Bank 9381 0726 Dr Tim Isaacs [email protected] Stephanie Durham Coordinator Assoc. Prof. Mariapia Degli-Esposti 9381 0862 Co-Director, Centre for Experimental [email protected] Immunology; Assoc.
    [Show full text]
  • View the Program Here
    Annual Meeting 2020 Progressing precision medicine, disease prevention and control 14-16 October 2020 Live streamed from Sydney About the Academy The Australian Academy of Health and Medical Sciences is the impartial, authoritative, cross-sector voice of health and medical science in Australia. We advance health and medical research in Australia and its translation into benefits for all, by fostering leadership within our sector, providing expert advice to decision makers, and engaging patients and the public. We are an independent, interdisciplinary body of Fellows – elected by their peers for their outstanding achievements and exceptional contributions to health and medical science in Australia. Collectively, they are a representative and independent voice, through which we engage with the community, industry and governments. The Academy is uniquely positioned to convene cross-sector stakeholders from across Australia to address the most pressing health challenges facing society. We focus on the development of future generations of health and medical researchers, on providing independent advice to government and others on issues relating to evidence based medical practice and medical researchers, and on providing a forum for discussion on progress in medical research with an emphasis on translation of research into practice. The Academy is registered with the Australian Charities and Not-for-profits Commission (ACNC) and is endorsed as a deductible gift recipient. www.aahms.org We are grateful to our generous event sponsors Platinum Sponsors With Additional Support From Venue Sponsor #AAHMS2020 @MedSciAcademy @AAHMS_Health 14 October 2020 Workshop live streamed from Sancta Sophia College, University of Sydney Wednesday 14 October 2020 MENTORSHIP WORKSHOP (for AAHMS mentees, mentors and invited participants (online) Engaging with policy and policymakers.
    [Show full text]
  • Request for Formal Retraction of Infamous Australian Paradox Paper
    Rory Robertson 20 April 2016 Request for formal retraction of infamous Australian Paradox paper Dear members of the Senior Executive Group of the University of Sydney, and outside observers, I'm sorry to have to write to many of you again about the Charles Perkins Centre's Australian Paradox scandal. I will try to be brief, providing the relevant history and a four-point argument for the formal retraction of the infamous paper: http://sydney.academia.edu/AlanBarclay ; http://www.australianparadox.com/pdf/OriginalAustralianParadoxPaper.pdf For starters, note that an ABC Lateline report last week confirmed my assessment that the paper is extraordinarily faulty, has false conclusions and works to damage public health: http://www.abc.net.au/lateline/content/2015/s4442720.htm As I explained in 2014 to the Academic Board - which did not reply - Deputy Vice-Chancellor (Research) Professor Jill Trewhella's "Initial Inquiry" into this matter was an epic fail, with the Initial Inquiry Report wrong on five of its seven "Preliminary Findings of Fact": http://www.australianparadox.com/pdf/Letter-Academic-Board-Inquiry-Report.pdf Disturbingly, Professor Trewhella and her hand-picked independent investigator Professor Robert Clark AO combined to blatantly "bury" the fact that the Australian Paradox paper features a faked, falsified, made-up flat line. Call it whatever you like, but please check out Figure 6 (p.5 below). The suppression of the fake-data issue is “PROBLEM 1” in my response to the mistake-riddled Initial Inquiry Report: http://www.australianparadox.com/pdf/RR-response-to-inquiry-report.pdf Further, Professor Trewhella and Professor Clark combined "not to notice" that the authors’ own published charts of valid indicators - reproduced on the next three pages - spectacularly contradict the author’s mistaken claim of "a significant and substantial decline" in the consumption of added sugar over their chosen 1980-2010 timeframe.
    [Show full text]
  • Finding Cures for Cardiovascular Disease Through World-Class Medical Research 02 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 03
    IMPACT REPORT 2019 Finding cures for cardiovascular disease through world-class medical research 02 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 03 For years the Victor Chang Cardiac Research Institute has Contents been Australia’s home of heart research. Since , the Institute has made an unshakeable contribution to the fight against About Us 4 Heart Disease Statistics 6 cardiovascular disease, and that PATIENT STORY SCAD Survivor 8 makes us overwhelmingly proud. Chairman’s Report 10 Executive Director’s Report 14 In ­­ we farewell our PATIENT STORY Cardiac Arrest Survivor 16 Organisational Structure 17 pioneering Executive Director, Board of Directors 18 Professor Bob Graham. 25 years of discovery 20 PROFILE Professor Bob Graham 24 Nevertheless, we are confident PROFILE Professor Diane Fatkin 34 that in Professor Jason Kovacic PROFILE Professor Livia Hool 38 Research Divisions Overview 42 we have a champion who will not Victor Chang Cardiac Research Institute Innovation Centre 44 only continue this legacy but take Sohn Hearts & Minds the Institute to the next level, as Investment Leaders Conference 46 Heart Health Checks 48 the new leader of the organisation. Statement of Income and Expenditure 49 Achievements and Awards 50 Fundraising Events 52 Supporters and Acknowledgments 54 This special 25th Anniversary edition is dedicated Support Life-Saving Heart Research 57 to you, our loyal supporters. After a quarter of a century, thanks to you, we’re only just getting started. Here’s to another 25 illustrious years! 04 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 05 About Us Our Mission Our Statistics Australia’s home The relief of pain and suffering and the promotion of wellbeing, of heart research through an understanding of the fundamental The Victor Chang Cardiac Research mechanisms of researchers and staff cardiovascular biology in Institute is dedicated to finding cures health and disease.
    [Show full text]
  • 2020 POSTGRADUATE and ECR CANCER RESEARCH SYMPOSIUM DAY 1 Tuesday 10Th November 2020
    REGISTRATION LINK 2020 POSTGRADUATE AND ECR CANCER RESEARCH SYMPOSIUM DAY 1 Tuesday 10th November 2020 2:00 WELCOME Rebecca Venchiarutti and Natalia Pinello, PGSWG Chairs 2:05 OPENING ADDRESS Prof Anna DeFazio CRN Interim-Chair, Head of the Gynaecological Oncology Research Program at the Westmead Institute for Medical Research, and Director of the Centre for Cancer Research. University of Sydney Chair in Translation Cancer Research, Sydney West TCRC Session 1: Cancer immunology and immunotherapy Chair: Natalia Pinello 2.15 Ms Rebecca Simpson #001 Enterotypes resolve microbial associations with cancer immunotherapy outcomes Charles Perkins Centre, Melanoma Institute of Australia & Central Clinical School 2.25 Ms Ashleigh Sharman #002 Investigation of Potential Therapeutic Targets for Immunotherapy in Cutaneous Squamous Cell Carcinoma of the Head and Neck School of Medical Sciences 2.35 Dr Wei Jiang #003 Prophylactic donor-derived tumour antigen specific T cells in combination with multiple pathogen specific T cells for prevention of disease relapse and infection in patients undergoing allogeneic haemopoietic stem cell transplant (HSCT) for acute myeloid leukaemia (AML) or high-risk myelodysplasia (MDS): The INTACT Trial Woolcock Institute of Medical Research & Westmead Clinical School 2.45 Ms Ruth Allen #004 Unravelling the Role of Immune Cells Targeted by Immunotherapy Charles Perkins Centre & School of Medical Sciences 2.55 Ms Grace Attrill #005 Tumour-specific, tumour-resident, cytotoxic T cells are associated with reduced recurrence
    [Show full text]
  • Our First User Group Meeting in Sydney! Join Us for the 10X Genomics User Group Meeting in Sydney on Tuesday the 11Th of December 2018
    Welcome to Our First User Group Meeting in Sydney! Join us for the 10x Genomics User Group Meeting in Sydney on Tuesday the 11th of December 2018. This event includes scientific talks by local users and latest application/product update from 10x Genomics. It provides a unique opportunity to network, discuss and interact with colleagues in the community and experts from the 10x team. Date Time Location Tuesday 11th of 10:00am - 4:00pm Sydney - Garvan-Weizmann Center for Cellular Genomics, Seminar Room December 2018 Followed by drinks TIME SPEAKER & TOPIC 9:30am - 10:00am Registration open 10:00am - 10:15am Introduction - Josh Warburton, Business Development Manager, Decode Science 10:15am - 10:35am Biology at True Resolution: Version 3 Chemistry and 10x Genomics Product Portfolio - Giovanna Prout, Director, Single Cell Products, 10x Genomics 10:35am - 11:05am Single Cell RNA-sequencing to Decipher Mechanisms of Drug-resistance in Neuroblastoma - Daniel Carter, PhD, Project Leader, Children’s Cancer Institute Australia 11:05am - 11:30am Morning Tea 11:30am - 12:00noon Single Cell Sequencing Meets Population Genetics - Joseph Powell PhD, Associate Professor, Garvan- Weizmann Center for Cellular Genomics 12:00noon - 12:20pm 10x Genomics Software Solutions: A Run Through the Pipelines with a Dive into the Loupe Cell Browser - Michael Campbell PhD, Senior Software Field Operations Engineer, 10x Genomic 12:20pm - 12:45pm Sponsored talk: A New Way to Sequence More Single Cells - Anthony Beckhouse PhD, Global Field Application Specialist, BGI Australia
    [Show full text]
  • Today's Research Tomorrow's Cure
    2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
    [Show full text]
  • Research Excellence
    Research excellence We are one of the world’s top research universities and a member of Australia’s prestigious Group of Eight network and the Association of Pacific Rim Universities. We also partner with others that excel in research, including Harvard, Stanford, Utrecht University, Tsinghua University and the University of Hong Kong. sydney.edu.au/research Our research is driven by the big such as health, climate change and − the Australian Institute for picture and we provide a hub for food security. Our multidisciplinary Nanoscale Science and industry, government and community research centres include: Technology that is transforming groups to collaborate with us and Sydney into a global hub for connect with our researchers and − the Charles Perkins Centre discovering and harnessing new students. The development of major dedicated to easing the global science at the nanoscale. innovations such as the black box burden of obesity, diabetes, recorder, pacemaker, Wifi and the cardiovascular disease We invest in research that changes bionic ear started here. and related conditions the way we think about the world. − the Brain and Mind Centre, a Find out more about our research: We are also home to 90 world- leader in research, education sydney.edu.au/research renowned multidisciplinary research and treatment of a range and teaching centres that are of diseases from autism to strongly positioned to tackle some schizophrenia, depression, of the world’s biggest challenges, dementia and Parkinson’s disease In the top 50 All our research We are tripling of the world’s best is ranked at world our investment in CRICOS 00026A CRICOS research universities standard or above research (QS World University (Excellence in Research for (University of Sydney Rankings 2018) Australia report, 2015) Strategic Plan, 2016-20 ) – POSTGRADUATE RESEARCH HOW TO APPLY HOW TO APPLY RESEARCH These steps will guide you in applying for a research – master's or PhD degree at the University of Sydney.
    [Show full text]
  • Associations of Sarcopenic Obesity with the Metabolic Syndrome and Insulin
    TITLE: Associations of Sarcopenic Obesity with the Metabolic Syndrome and Insulin Resistance over Five Years in Older Men: The Concord Health and Ageing in Men Project 1,2 3,4,5 4 4 AUTHORS: David Scott , Robert Cumming Vasi Naganathan , Fiona Blyth , David G Le Couteur6, David J Handelsman7, Markus Seibel8 , Louise M Waite4, Vasant Hirani 5,9 AFFILIATIONS: 1 School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia 2 Department of Medicine and Australian Institute of Musculoskeletal Science, Melbourne Medical School – Western Campus, The University of Melbourne, St Albans, Victoria, Australia 3 School of Public Health, University of Sydney, New South Wales, Sydney, Australia. 4 Centre for Education and Research on Ageing, Concord Hospital, University of Sydney, New South Wales, Sydney, Australia. 5 The ARC Centre of Excellence in Population Ageing Research, University of Sydney, New South Wales, Sydney, Australia. 6 ANZAC Research Institute & Charles Perkins Centre, University of Sydney, New South Wales, Sydney, Australia. 7 Department of Andrology, Concord Hospital & ANZAC Research Institute, University of Sydney, New South Wales, Sydney, Australia. 8 Bone Research Program, ANZAC Research Institute, and Dept of Endocrinology & Metabolism, Concord Hospital, The University of Sydney, New South Wales, Sydney, Australia. 9 School of Life and Environmental Sciences, Charles Perkins Centre, University of Sydney, New South Wales, Sydney, Australia. CORRESPONDING AUTHOR: 1 Dr. David Scott School of Clinical Sciences at Monash Health, Monash University Clayton, Victoria, Australia 3168 Email: [email protected] Telephone: +61 3 8572 2397 Fax: +61 3 9594 6437 FUNDING: This work was supported by the National Health and Medical Research Council (project grant number 301916) and the Ageing and Alzheimer’s Institute.
    [Show full text]
  • Charles Perkins Centre Engagement with Industry Guidelines
    CHARLES PERKINS CENTRE Engagement with industry guidelines 1 The Charles Perkins Centre’s (CPC) mission is to ease the burden of obesity, diabetes and cardiovascular disease by translating research into improved health outcomes for individuals, communities and populations, both nationally and internationally. 2 Engagement with industry is appropriate and necessary to achieve the CPC mission. Industries relevant to the CPC research strategy include, among others, the food, dietary supplement and physical activity sectors, the pharmaceutical industry, technology and medical devices, urban design and development, health and medical insurance, and health service providers. Collectively, each of these industries’ goods and services are consumed daily by billions of citizens. Solutions to obesity, diabetes and cardiovascular disease will be highly relevant to the future of these industries, and their strategic engagement with researchers and educators will be important in progressing toward these solutions. Government and government agencies are not included under these guidelines. 3 The CPC will actively seek to engage with industry in support of its mission. Types of engagement with industry might include: Donations or sponsorship of CPC activities (research, educational, clinical, translational) Direct funding or in-kind support of CPC research projects Joint programs of research on specific basic, clinical or translational research issues Consultancy (paid or unpaid) Knowledge mobility through secondments to and from industry under
    [Show full text]